RxDoctor Payments DataLook up a doctor →

Blair Kirkpatrick, MD

Gastroenterology · Norman, OKNPI 1942680087

Payments from drug & device makers

$11,133in general payments, 2019–2025

Across 617 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Gilead$694
  • Johnson & Johnson$618
  • Bristol Myers Squibb$614
  • plus $4K from 23 others

What the payments were for

  • Food & beverage$11,00199%
  • Education$1321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,133 in reported general payments places this provider in the 70th percentile of 133 gastroenterology providers in Oklahoma.

See all gastroenterology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$238,354
Medicare patients
1,073
Services billed
3,137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide22$19,929
ZenpepLipase/Protease/Amylase14$19,627
TrulancePlecanatide15$11,089
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates123$7,148
Budesonide DrBudesonide27$6,293
Omeprazole240$5,365
Mesalamine11$4,496
Colestipol Hcl35$3,417
Ursodiol12$2,238
Pantoprazole Sodium110$1,944
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl92$1,442
Dicyclomine Hcl57$1,424
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl69$1,186
Sucralfate31$1,121
Ondansetron OdtOndansetron29$1,102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$2,668$19,92922 claims
Aimmune Therapeutics, Inc.Zenpep$303$19,62714 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$1,233$11,08915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 133 gastroenterology providers in Oklahoma.

Other gastroenterology in Norman

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →